BridgeBio Pharma Inc (BBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BridgeBio Pharma Inc (BBIO) has a cash flow conversion efficiency ratio of 0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-109.57 Million) by net assets ($-1.92 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BBIO net asset quality score to measure how much of total assets are equity-financed.
BridgeBio Pharma Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how BridgeBio Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BridgeBio Pharma Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
BridgeBio Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BridgeBio Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Masco Corporation
NYSE:MAS
|
-2.926x |
|
Pinnacle Financial Partners, Inc.
NASDAQ:PNFP
|
0.059x |
|
Cemex SAB de CV ADR
F:CEXA
|
0.009x |
|
LTIMindtree Limited
NSE:LTIM
|
0.057x |
|
Unibail-Rodamco-Westfield
PA:URW
|
0.116x |
|
SANDS CHINA ADR/1 O.N.
F:599
|
N/A |
|
Xian LONGi Silicon Materials Corp
SHG:601012
|
0.045x |
|
Henkel AG & Co. KGaA vz. (Pref Shares)
XETRA:HEN3
|
0.034x |
Annual Cash Flow Conversion Efficiency for BridgeBio Pharma Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of BridgeBio Pharma Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market value of BridgeBio Pharma Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.46 Billion | $-520.73 Million | 0.357x | -9.12% |
| 2023-12-31 | $-1.34 Billion | $-527.72 Million | 0.393x | +16.65% |
| 2022-12-31 | $-1.24 Billion | $-419.49 Million | 0.337x | -41.42% |
| 2021-12-31 | $-865.58 Million | $-497.93 Million | 0.575x | +115.53% |
| 2020-12-31 | $107.89 Million | $-399.71 Million | -3.705x | -595.41% |
| 2019-12-31 | $475.98 Million | $-253.59 Million | -0.533x | -139.58% |
| 2018-12-31 | $-101.50 Million | $-136.64 Million | 1.346x | +81.82% |
| 2017-12-31 | $-54.69 Million | $-40.49 Million | 0.740x | -- |
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM);… Read more